ESMO 2022 | Key takeaways in breast cancer from ESMO 2022

Vivianne Tjan-Heijnen, MD, PhD, Maastricht University, Maastricht, Netherlands, shares key takeaways from the European Society for Medical Oncology (ESMO) 2022 Congress in breast cancer, which includes data indicating patients with double hormone receptor positive (HR+) disease and who are at risk of distant recurrence should be treated with extended endocrine treatment, consisting of 2-3 years of tamoxifen followed by 5 years of aromatase inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.